Clinical Trial Update: Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating inhaled interferon-β for COVID-19 has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome Coronavirus 2

Drugs mentioned

• Inhaled interferon-β (interferon-β)

Snippet

Sponsor: Synairgen Research Ltd. | Conditions: Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19 | Phase 3 | Status: COMPLETED | Results posted: 2023-03-27